Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis

NCT00991861 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Actinic Keratosis

Interventions

DRUG: LAS41007 o.d.
DRUG: LAS41007 b.i.d.
DRUG: LAS106521

Sponsor

Almirall, S.A.